BeOne Medicines (06160) Opens Over 7% Higher as Nine-Month Adjusted Net Profit Rises 96% Year-on-Year, Citi Notes Brukinsa Continues to Outperform Expectations

BeOne Medicines (06160) opened more than 7% higher, rising 7.57% as of press time to HK$267, with a turnover of HK$80.3136 million.

On the news front, BeOne Medicines recently announced its third-quarter 2026 results, with total revenue of approximately US$1.89 billion, up 34% year-on-year; net product revenue of approximately US$1.855 billion, up 33% year-on-year. Net profit was approximately US$385 million, up 208% year-on-year; adjusted net profit was approximately US$539 million, up 77% year-on-year. For the first three quarters of 2026, total revenue was approximately US$5.108 billion, up 33% year-on-year; net profit was US$849 million, up 285% year-on-year; adjusted net profit was approximately US$1.358 billion, up 96% year-on-year.

Citi released a research report stating that BeOne Medicines once again delivered a strong quarterly performance, with total revenue of approximately US$1.89 billion, beating the bank's and market expectations by 1% and 8%, mainly driven by Brukinsa's continued better-than-expected performance, supporting the company in once again raising its full-year 2026 revenue guidance from the previous US$6.6 billion to US$6.8 billion range to between US$6.9 billion and US$7.0 billion.

On the product side, Brukinsa revenue reached approximately US$1.39 billion, up 11% quarter-on-quarter, with US sales exceeding US$1 billion for the first time, while growth in China and other regions globally remained healthy.